Aptus Capital Advisors LLC Acquires New Shares in Sanofi (NASDAQ:SNY)

Aptus Capital Advisors LLC bought a new stake in shares of Sanofi (NASDAQ:SNY) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 4,218 shares of the company’s stock, valued at approximately $205,000.

Several other institutional investors also recently bought and sold shares of SNY. Boston Partners lifted its stake in shares of Sanofi by 0.3% in the first quarter. Boston Partners now owns 13,066,403 shares of the company’s stock worth $635,280,000 after buying an additional 33,657 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Sanofi by 19.0% during the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after acquiring an additional 1,370,232 shares during the period. Mondrian Investment Partners LTD boosted its holdings in Sanofi by 43.1% during the first quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock valued at $192,023,000 after acquiring an additional 1,190,141 shares during the period. Raymond James & Associates lifted its position in shares of Sanofi by 16.2% during the 2nd quarter. Raymond James & Associates now owns 2,689,876 shares of the company’s stock worth $130,513,000 after purchasing an additional 374,621 shares during the last quarter. Finally, Equity Investment Corp boosted its stake in Sanofi by 23.0% during the 1st quarter. Equity Investment Corp now owns 2,393,474 shares of the company’s stock valued at $116,323,000 after purchasing an additional 447,872 shares during the period. 10.04% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have issued reports on SNY. StockNews.com raised Sanofi from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Argus upped their target price on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Sanofi has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Stock Up 1.7 %

SNY opened at $58.53 on Thursday. The company has a market capitalization of $148.24 billion, a P/E ratio of 29.41, a P/E/G ratio of 1.60 and a beta of 0.60. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The firm’s fifty day moving average price is $52.43 and its two-hundred day moving average price is $49.67. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $58.97.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. The business had revenue of $10.75 billion for the quarter, compared to analysts’ expectations of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.95 earnings per share. On average, analysts anticipate that Sanofi will post 4.23 EPS for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.